Lung cancer statistics, 2023
2024/01/27 by Tyler B. Kratzer, Priti Bandi, Neal D. Freedman +4 · 32 citations
Medicine · #Global Cancer Incidence and Screening #Lung Cancer Diagnosis and Treatment #Colorectal Cancer Screening and Detection
paper · pdf · doi:10.1002/cncr.35128
Abstract
Despite decades of declining mortality rates, lung cancer remains the leading cause of cancer death in the United States. This article examines lung cancer incidence, stage at diagnosis, survival, and mortality using population-based data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries. Over the past 5 years, declines in lung cancer mortality became considerably greater than declines in incidence among men (5.0% vs. 2.6% annually) and women (4.3% vs. 1.1% annually), reflecting absolute gains in 2-year relative survival of 1.4% annually. Improved outcomes likely reflect advances in treatment, increased access to care through the Patient Protection and Affordable Care Act, and earlier stage diagnosis; for example, compared with a 4.6% annual decrease for distant-stage disease incidence during 2013-2019, the rate for localized-stage disease rose by 3.6% annually. Localized disease incidence increased more steeply in states with the highest lung cancer screening prevalence (by 3%-5% annually) than in those with the lowest (by 1%-2% annually). Despite progress, disparities remain. For example, Native Americans have the highest incidence and the slowest decline (less than 1% annually among men and stagnant rates among women) of any group. In addition, mortality rates in Mississippi and Kentucky are two to three times higher than in most western states, largely because of elevated historic smoking prevalence that remains. Racial and geographic inequalities highlight longstanding opportunities for more concerted tobacco-control efforts targeted at high-risk populations, including improved access to smoking-cessation treatments and lung cancer screening, as well as state-of-the-art treatment.
Citations
Cited by
- Cancer statistics, 2026
- The Need for Contemporary, Diverse, and Annotated Datasets to Advance AI in Lung Cancer Screening
- Stress Management Program for Scanxiety in People With Advanced Lung Cancer: Intervention Adaptation and Stakeholder Feedback
- Simultaneous immunomodulation and epithelial-to-mesenchymal transition drives lung adenocarcinoma progression
- ZIP10 drives radioresistance and malignant progression in lung adenocarcinoma by inhibiting the Hippo pathway via a Zinc-LATS axis
- Uncertainty-Aware Learning Policy for Reliable Pulmonary Nodule Detection on Chest X-Ray
- Trends in lung cancer- and chronic obstructive pulmonary disease (COPD)-related mortality among older adults in the United States, 1999–2024: A CDC WONDER database analysis
- RAF and MEK Inhibitors in Non-Small Cell Lung Cancer. [europepmc]
- Lung Cancer Screening in the US, 2022. [europepmc]
- Editorial: Real-world data and real-world evidence in lung cancer. [europepmc]
- The genomic landscape of lung cancer in never-smokers from the Women's Health Initiative. [europepmc]
- How General and Inflammatory Status Impacts on the Prognosis of Patients Affected by Lung Cancer: State of the Art. [europepmc]
- Adiponectin Receptor Agonist AdipoRon Inhibits Proliferation and Drives Glycolytic Dependence in Non-Small-Cell Lung Cancer Cells. [europepmc]
- Cinobufagin inhibits M2‑like tumor‑associated macrophage polarization to attenuate the invasion and migration of lung cancer cells. [europepmc]
- Identification of a Plasma Exosomal lncRNA- and circRNA-Based ceRNA Regulatory Network in Patients With Lung Adenocarcinoma. [europepmc]
- Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review. [europepmc]
- MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters. [europepmc]
- Updates in Management of Unresectable Stage III Non Small Cell Lung Cancer: A Radiation Oncology Perspective. [europepmc]
- Cancer statistics, 2025. [europepmc]
- Landscape of 2D Deep Learning Segmentation Networks Applied to CT Scan from Lung Cancer Patients: A Systematic Review. [europepmc]
- Exploring manzamine a: a promising anti-lung cancer agent from marine sponge Haliclona sp. [europepmc]
- Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions. [europepmc]
- Annual Report to the Nation on the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic. [europepmc]
- The Current Roadmap of Lung Cancer Biology, Genomics and Racial Disparity. [europepmc]
- The Application of Dendritic Cells Vaccines in Tumor Therapy and Their Combination with Biomimetic Nanoparticles. [europepmc]
- Deep learning object detection-based early detection of lung cancer. [europepmc]
- Diagnostic accuracy of serum biomarkers MMP11 and SPP1 in non-small cell lung cancer: an analysis of sensitivity, specificity, and area under the curve. [europepmc]
- Robotic-assisted bronchoscopy-advancing lung cancer management. [europepmc]
- Probiotics and Cancer: Mechanistic Insights and Organ-Specific Impact. [europepmc]
- In situ-formed immunotherapeutic hydrogel containing sphingosine-1-phosphate for enhanced lung cancer immunotherapy. [europepmc]
- Synthesis, antiproliferative activity targeting lung cancer and in silico studies of hydroxypiperidine substituted thiosemicarbazones. [europepmc]
- Critical role for a high-plasticity cell state in lung cancer. [europepmc]
Related